TW201004635A - Modulation of immune response by oral consumption of flammulina velutipes products - Google Patents

Abstract

The present invention provides a food composition containing Flammulina velutipes powder for modulating immune response. The present invention also provides a feed composition containing Flammulina velutipes powder for modulating immune response. The present invention provides a pharmaceutical composition containing Flammulina velutipes powder for modulating immune response. The food composite, feed composition and pharmaceutical composition in accordance with the present invention are prepared by convenient processes and are demonstrated to be capable of modulating specific or non-specific immune responses.

Description

201004635 IX. Description of the invention: [Technical field to which the invention pertains] The present invention relates to a food containing gold needles ve/im.pes as a main functional material, and mainly provides a non-specific immune response and specificity by using acupuncture products. A food or feed supplement that has an effect such as an immune response. [Prior Art] Recent scientific research has found that medicinal and medicinal mushrooms have many physiological functions. 'Chien c. Μ. et al. 2004 & valence mountain · heart α / C / ^ m (1) " less 12th volume 5603 -5609 pages, and Gao et al., 2005, in /wmw«o/<?gZ.ca/ /«vesiz'gaiiow, Vol. 34, pp. 171-198, which mentions the choice of anti-tumor, Activates lymphocytes and activates physiological activities such as natural killer cells. Flammulina velutipes, also known as the golden mushroom and golden mushroom, is officially known as the velvet mushroom, belonging to the Basidiomycetes, Agaricidae (Jgar/ca/e·?·), and the mouth grinding family (JWc/zo/owaiaceae). It is distributed in warm and subtropical regions around the world and is a common edible wild mushroom. Flammulina velutipes belongs to the woody saprophytic wild mushroom, which is mainly grown in spring, autumn and winter. It is several days old and has soft meat. The artificial planting system is now mainly cultivated by using greenhouses to control the use of wood chips, rice bran and water as the main source of nutrients. FlP-fve (Republic of China Patent No. 34〇848) is a fungal immunomodulatory protein (FIP) purified from Golden Needle and is also the most active active ingredient in Flammulina velutipes. Invented by Mr. Ke Junliang, Mr. and Mr. Ke Junliang, with the ability to agglutinate humans 201004635 red blood cells, inhibiting systemic allergic reactions induced by bovine serum albumin (BS A), and inhibiting albumin (Ovalbumin, OVA) Systemic allergic reaction symptoms, in the in vitro test vz7ro_ test) can activate human peripheral blood spleen cells to promote their proliferative capacity. In addition, Feiyifu also has the effect of inhibiting tumor activity (Republic of China Patent Application No. 09213 6094). However, the above patents emphasize the development of pharmaceuticals. Although oral Feiyifu has anti-tumor activity, it is still unclear whether it is also immune-regulated in vivo. Therefore, it is hoped that the immune response can be regulated without time-consuming preparation of purified protein. Edible Flammulina foods have the effect of immune regulation. SUMMARY OF THE INVENTION In view of the above-mentioned shortcomings of the prior art, the applicant is devoted to studying the effect of the application of the Flammulina velutipes product in regulating the immune response, and through continuous sputum test and research, it is confirmed that the Flammulina velutipes powder promotes the immune response. Efficacy and its potential for regulating immune responses. Accordingly, an object of the present invention is to provide a food composition feed composition and a pharmaceutical composition comprising the Flammulina velutipes powder p〇w (4), which are simple in preparation and which do not require an additional complicated purification procedure. And the food composition, the feed composition and the pharmaceutical composition of the present invention: by activating lymphocytes and activating natural killer cells, the immune response of the vertebrate (especially human or other mammal) is adjusted, and the J is lowered. The risk of suffering from a disease or treating a disease (such as a tumor, autologous exemption 201004635 epidemic disease, etc.). In a first aspect, the invention provides a food composition for modulating an immune response' comprising a Flammulina velutipes powder. Preferably, the food composition is prepared by the following steps: providing fresh Flammulina velutipes fruit body; homogenizing the Flammulina velutipes fruit body into a Flammulina velutipes liquid; drying the I-needle garlic liquid to form a Golden Needle powder; and the Flammulina velutipes The powder is made into a food composition for use as an immune response.

Preferably, the food composition is prepared by the following steps: providing a mushroom body; drying the mushroom body; drying the mushroom body to obtain the mushroom powder; and grinding the dried and preparing the mushroom It is used as a food composition to regulate immune response. In a second aspect, the present invention provides a feed composition for modulating an immune response comprising a Flammulina velutipes powder.

Preferably, the feed composition is prepared by the following steps: supplying a fresh gold (four) sub-solid; homogenizing the golden needle body into a golden needle body to 'dry the mushroom liquid to form a mushroom powder; and the needle The mushroom powder is made into a feed composition for feeding animals and regulating the reaction. Preferably, the former is supplied to the Flammulina velutipes fruiting body, and the fruit composition is made into a feed composition. The feed composition is prepared by: drying; drying the mushroom body; grinding the dried to obtain the mushroom powder; and the mushroom powder as a breeding animal and regulating the immune response in the third Aspects The present invention provides a pharmaceutical composition for the regulation of an immune response, 201004635, an excipient. It comprises a mushroom powder and a pharmaceutically acceptable carrier or preferably, the aforementioned acerola powder is obtained by the steps of: providing a fresh gold needle borrowing body; homogenizing the golden needle body into a golden needle garlic liquid; and drying The Flammulina velutipes liquid forms a Flammulina velutipes powder.

Preferably, the aforementioned Flammulina velutipes powder is obtained by the following steps: providing a Flammulina velutipes fruit body; drying the Flammulina velutipes fruiting body; and grinding the dried Flammulina velutipes fruit body to obtain Flammulina velutipes powder. Since the present invention can purify a specific protein which modulates an immune response without a time-consuming preparation procedure, it can exert an immunomodulatory effect, and thus has the advantage of achieving cost reduction as a health food application. DETAILED DESCRIPTION OF THE INVENTION The term "irninune response" as used herein refers to a foreign or endogenous immune stimulant that stimulates a response elicited by the immune system. The term "modulating" as used herein, as used herein, refers to the promotion or inhibition of immune responses by immune cells within the immune system to the aforementioned immune stimuli caused by foreign or endogenous immune stimuli. In the "regulating immune response" referred to in the present invention, it is preferred to increase the proliferative activity of the immune cells, the amount of cytokine secretion, the poisoning/tongue of the natural killer cells, and the amount of the secretion of I in the serum. According to the invention, the term "fruiting body" as used herein means a vegetative part of a fungus, also known as a basidiophore. s 201004635 According to the present invention, Flammulina velutipes ^ ^. Liquid mash is a mixed solution produced by mashing or homogenization of a ginseng mushroom fruit body through a high-speed mixing machine or a homogenizer. In accordance with the present invention, the step of drying can be lyophilized, spray dried or 50-95. (: hot air drying is carried out, 卩 坪 雾 雾 雾 ,, η ', 入 selectively' the drying step is carried out by lyophilization or 50-95 t hot air drying. According to the food composition of the present invention, the system may have The gold (tetra) powder is prepared by mixing with other food additives, wherein the food composition may be in liquid or solid form, for example, but not limited to, drink, dairy (dairy)

Pr〇dUCt) or fermented dairy (fementedmilk). The specific embodiment of the food composition according to the present invention is a liquid form which has not been prepared by cooking, but it can be understood that other forms of cooking or powder, spin, gel, paste form are implemented. The examples are also covered by this issue. According to the present invention, the golden needle powder can also be prepared into a powder by grinding or pulverizing the dried golden needles. Preferably, the food composition is taken in an amount of 1000 mg to 3000 mg of enoki mushroom powder per kilogram of body weight per day; more preferably, the food mash is 5 〇〇 to (9) per kilogram of body weight per day. The number of tablets of the Flammulina velutipes is taken; and more preferably, the food composition is taken in an amount of just ton to (7) (10) of the golden needle garlic powder per a pound of body weight per a pound. The feed composition according to the present invention may be prepared by mixing Flammulina velutipes powder and other feeds, and the specific 201004635 embodiment of the feed composition according to the present invention is a liquid form which has not been prepared by cooking. It will be understood, however, that other specific examples of cooking or in the form of powders, ingots, gels, and pastes are also encompassed by the present invention. Preferably, the feed composition according to the present invention may be a tablet, a suspension, a dried oral supplement, or a wet 〇ral supplement. s, dry tube feeding or wet tube_feeding. Preferably, the feed composition is silvered at a dose of 〇〇mg to 3000 mg of Flammulina velutipes powder per kilogram of body weight per day; more preferably, the medicament is 500 mg to 2000 mg per kilogram of body weight per kilogram The dose of Flammulina velutipes powder is fed; and more preferably, the medicament is fed at a dose of 100 mg to 1000 mg of Flammulina velutipes powder per kilogram of body weight per kilogram. According to the "pharmaceutically acceptable carrier" of the present invention, if the pharmaceutical composition is in an oral form, the carrier can protect the pharmaceutical composition from the decomposition of the digestive system before it reaches the site of action, and loses its utility' and / or can promote the release of drugs and effects. The "pharmaceutically acceptable excipient" according to the present invention is for increasing the uniformity, stability, and reducing the irritancy, adverse odor, etc. of the drug, such as sugar alcohol, starch or other persons having ordinary knowledge in the art. Known excipients. Preferably, the pharmaceutical composition is administered at a dose of 1 to 3000 mg of Flammulina velutipes powder per kilogram of body weight per day; more preferably, the pharmaceutical 201004635 composition is 500 mg to 2000 per kilogram of body weight per day. A dose of mg of the gold needle powder is administered; and more preferably, the pharmaceutical composition is administered at a dose of 100 mg to 1000 mg of Flammulina velutipes powder per kilogram of body weight per kilogram. The present invention will be further illustrated by the following examples, but it should be understood that these examples are for illustrative purposes only and are not to be considered as limiting. · © The invention uses Jinzhengyi ve/wi/pe·?) as a material, and the dried garlic powder is prepared as a suspension solution in phosphate buffer solution at low dose (2.1 mg/mouse) and high dose (18.9 mg). /mouse) was used as a control group, and phosphate buffer solution (PBS) was used as a control group, and a commercially available Ganoderma lucidum health food grape 'King Lingzhi Wang (6.22 mg/mouse) was used as a positive control group. It has been found that the Flammulina velutipes powder has the efficacy of modulating the immune response of the present invention. The present invention confirms the efficacy of the oral immunoglobulin by regulating the non-specific immune response; and evaluating the OVA-specific immune response pattern. #Example General experimental materials and animal test h Preparation of Flammulina velutipes powder: Use homogenizing equipment to whipped fresh Flammulina velutipes fruit body into Flammulina velutipes juice, and then dry it with cold image, spray drying or hot air drying at 50-95 °C. The golden needle juice is prepared into a powder sample of Flammulina velutipes; or the fresh Flammulina velutipes is directly dried by cold drying or hot air drying at 50, 95 ° C, and then ground to obtain a gold needle borrowing powder sample. The quantitative Flammulina velutipes powder was diluted with pb S into a 201004635 dose (94.5 mg/mL), low dose (10.5 mg/mL) Flammulina velutipes solution (as the feeding dose in the following examples), and stored in 4 refrigerators. In the test, the commercially available health food grape king Ganoderma lucidum was used as a positive control group, and PB s was prepared (6.5 5 mg/mouse) as a feeding dose, and stored in a 4 乞 refrigerator for use. 2 • Animal feeding: Female BALB/c mice weighing approximately 20-25 grams were purchased from the National Laboratory Animal Center (Taipei, Taiwan). During the feeding period, the temperature in the control room was 25 ± 2 C, the relative humidity was 65 ± 5%, and the light and dark cycle time was u hours. Feed and water were allowed to eat freely during the experiment. 3 · Cell line and culture: Mouse lymphoma is fine. Cell line intrusion (:-1 (eight 1 ' (: (: 1 '13-160) purchased from the Center for Bioresource Conservation and Research, Food Industry Development Research Institute 60147) The medium was supplemented with 1% fetal bovine serum (FBS) and 1% penicillin/streptomycin in RPMI. The culture conditions were cultured in 96-well plates at 37 ° C, 5 〇 / 〇 carbon dioxide ( 96 well plate. 4. Preparation of spleen cells: After the BALB/c mice were killed by c〇2, the intact spleen was taken from the abdominal cavity of the mice and placed in a Petri dish containing 6 mL of PBS. The spleen was ground in the frosted portion of the slide and centrifuged for 5 minutes at room temperature (3). After removing the supernatant, treat it with 1 mL of RBC lysis buffer for 3 minutes to remove red blood cells. Add 9mL pBs to uoo

ΓΡΠ 1 centrifugation lasted 5 minutes. The supernatant was then removed, and 10 mL of DMEM % nutrient was added to flush the cells and the cells were well mixed and used immediately. 12 201004635 4. Statistical analysis: Ten mice (n = 1 〇) were taken from each treatment group, three replicates per analysis. All data are broken through statistical software pc_SAs (Statisticai Analysis

System, SAS Institute Inc., USA) One-way difference analysis (ANOVA) (Least Significant Difference (LSD)» The probability of matching between the two treatment groups and the control group p < 〇〇 5, depending on Significant differences. Example 1 Evaluation of Non-Specific Immune Response Experimental Method 1 · Analysis of spleen cell metabolic activity: Analysis of spleen cell metabolic activity was carried out by a thiazole blue tetrazolium test [MTT assay]. The spleen cells of the fed mice were cultured in RPMI medium to prepare a cell suspension having a cell concentration of 5×10 6 cells/mL, and 50 pL of the cell suspension was inoculated into each well of a 96-well plate. After 72 hours, add 20 pL of MTT solution (please supply the source). After 5 hours of reaction, remove the supernatant by centrifugation, and add 80 μί of dimethyl argon (DMSO) to the dark chamber for 5 minutes to bind to the enzyme by immunosorbent. The absorbance at 540 nm was determined by an analytical microtiter ELISA microplate reader. 2. Analysis of spleen cell proliferation activity: Analysis of spleen cell proliferation activity was carried out by brominated deoxyribonucleoside (BrdU) cell proliferation: BrdU cell proliferation kit (Roche®). The spleen cells of the fed mice were cultured in RPMI medium to prepare a cell suspension having a cell concentration of 5×10 6 cells/mL, 13 201004635 50 pL of the cell suspension was inoculated into each well of a 96-well plate, and cultured 48 After 1 hour, add 1 〇pL of 1 mM Brdu per well, and after 24 hours, centrifuge at 13 rpm for 5 minutes to pellet the cells at the bottom of the 96-well plate. Remove the culture solution and rinse with PBS. The fix denate solution was removed after 3 minutes at room temperature. After washing, add 2 blocking solution to leave at room temperature for 90 minutes, and add 100 μί Oxidase-labeled anti-Brdu antibody solution (Anti_Brdu_PeroxidaseTM), leave it at room temperature for 9 minutes, wash and add TMB substrate solution to each well, and place at room temperature for about 3 times. After a minute, 25 pL of stop solution (1 Μ H2S04) was added. Finally, the absorbance at 450 nm was measured by an enzyme-binding immunosorbent assay (ELISA microplate reader). 3. IFN-γ secretion: 50 μί spleen cells (5χ1〇5 cells/well) treated with different feeding doses were added to a 96-well microtiter plate and cultured at 37 ° C under 5% CO 2 conditions. Cellulase was collected after an hour and analyzed using the bd Pharmingen IFN-® gamma OptEIATM Set kit. The capture antibody was pre-coated on a % well ELISA floppy disk. After adding 100 pL of capture antibody per well, at 4. (: The refrigerator is allowed to stand overnight. The next day, it is washed 5 times with the wash buffer, and then blocking is performed: 200 μM of blocking buffer is added to each well to reduce non-specificity. Sexual interference, washed one time with washing buffer 5 times 'addition of standard and cell culture solution or serum collected after treatment with various feeding doses, react for 2 hours, then wash 5 times with washing 201004635 buffer. The well was added to the loo pL detection antibody and avidin ΗΚΡ (avidin_HRp) for 1 hour, then washed 7 times with washing buffer, and colored in ABTS coloring system for about 30 minutes. After the measurement of the absorbance at 405 nm wavelength, each experiment has three repetitions and is compared with the standard curve to determine the amount of IFN-γ produced by the sample concentration. 4. IL-2 secretion: Take different feeding agents Amount of treated mouse spleen cells 5 〇 cell suspension sputum (5 x 1 〇 5 cells / well) was added to a 96-well microtiter plate and cultured at 37 ° C, 5% C 〇 2 for about 72 hours. Liquid to bd Pharmingen The IL-2 OptEIATM Set kit was used for quantitative analysis. The capture antibody was pre-coated on a 96-well ELISA floppy disk. After adding 100 capture antibodies to each well, the chamber was allowed to stand at 4 °c in a refrigerator. - Late. Wash the wash buffer 3 times the next day, and block the reaction: add 200 μί blocking buffer per well to reduce non-specific interference. After one hour, Wash the washing buffer 3 times, add the standard and the cell culture solution or serum collected by various feeding doses, react for 2 hours, then wash 5 times with washing buffer, and add 100 pL of detection antibody per well. After i hours, wash 5 times with washing buffer, add 100 mg of avidin _HRp (avidin HRp) per well, wash 7 times with washing buffer 1 hour later, and color with coloring system. After reacting for about 15 minutes at room temperature, immediately stop the reaction by adding a stop solution (1 M HjO4), and measure the absorbance at a wavelength of 45 〇 nm. Each experiment has three repetitions and is compared with the standard curve to Measured sample 15 201004635 The concentration is calculated. 5. Natural killer cell activity test: Count YAC-1 cells [as target cells] adjusted to lxlO6 cells/mL, YAC-1 cell solution per ml Add 1 〇 DIOC18(3) solution 'mix well and place at 37 ° C, stain for 20 minutes in 5% C02 incubator' and centrifuge at 1,300 rpm for 5 minutes. After removing the supernatant, add 1 〇 mL of wash buffer. The pellet was re-centrifuged once under the same conditions, and finally the pellet was suspended in RPMI medium containing 10% FBS, and was used. The spleen cells of the mice in the same treatment group [as effector cells] were adjusted, and the number of cells was adjusted to lxl07 cells/mL, and 400 pL of spleen cell solution was added to each of 100 pL of dyed YAC-1. The cytosol (acting cell/standard stem cell ratio is 40:1) (E/T ratio = 40:1), and the cells were uniformly mixed and placed in an incubator of 37 C '5 °/〇C〇2' for 4 hours. After removal, it was transferred into an ice bucket to terminate the reaction. Each tube was mixed with 5 pL of propidium iodide solution (PI solution), mixed at room temperature for 5 minutes, and analyzed by flow cytometry within 30 minutes. 6. Determination of total IgG in serum: assay analysis by mouse IgG Quantitative ELISA KitTM (eBi〇science®) 'Capture the capture antibody onto a 96-well ELISA floppy disk, add loo capture antibody to each well. Allow to stand overnight in a refrigerator at 4 °C. The next day, the cells were washed 3 times with washing buffer, and the barrier reaction was carried out. 200 pL of blocking buffer was added to each well to reduce non-specific interference. After 30 minutes, it was washed 3 times with washing buffer. The serum collected after the standard and the treatment groups were added, reacted for 1 hour, and then washed. 16 201004635 Su Buffer Wash 5 times 'Add 100 pL of HRP-detection antibody per well' 1 hour later Wash 5 times with Wash Buffer 'Addition of l〇〇pL antibiotics per well Protein_HRP (avidin-HRP), 1 hour later, washed 7 times with washing buffer, and colored by TMB coloring system. After reacting for about 15 minutes at room temperature, immediately add stop solution (st〇p Solution) (1M H2S04) Stop the reaction and measure the absorbance at 450 nm. Each experiment was repeated three times and compared to a standard curve, and the amount of production was calculated by measuring the concentration of the sample. The experimental design of Flammulina velutipes powder was formulated into high dose (94.5 mg/mL) and low dose (10.5 mg/mL) Flammulina velutipes solution, and the solution of 6.5 5 mg/mL was prepared as a positive control group. , pbs as a negative control group. The mice were fed a 200 μί enoki mushroom solution or a positive and negative control group for 40 days of sacrifice for daily feeding by tube feeding and feeding. After culturing the mouse spleen cells for 72 hours in vitro, the spleen cell proliferation activity of the mouse and the killing activity of natural kiUer cells (NK cells) in the spleen were measured; on the other hand, the cell culture medium was collected, and IFN was analyzed by ELISA. - γ and IL-2 and the amount of igG secreted in serum. The results showed that the high-dose Flammulina velutipes solution in mice (equivalent to 丨8.9 mg/mouse dose) could significantly increase the metabolic activity and proliferative activity of spleen cells in mice compared with the negative control group (ρ<0.05). The increase in metabolic activity relative to the negative control group was 12 1% in the sputum analysis (first panel); the percentage increase in the BrdU analysis relative to the negative control group was 17 201004635 20.9% (second panel); Compared with the negative control group, the cytotoxic activity of the mouse spleen was significantly increased (P<0_05), which was higher than the percentage of the cytotoxic killing of the group (13.7%) (third figure); The control group significantly increased the secretion of spleen cells (4) glycine IL_2 secretion (ρ<〇〇5), and the relative percentage increase of (4) control group (13) was 133.8/. (Fourth figure) and 43.6% (fifth); the percentage of total IgG secretion in the serum of the South African mice was significantly higher than that in the negative control group (ρ < 〇.〇5). 21.7% (fifth chart). Example 2: Evaluation of OVA-specific immune response Experimental method 1. Analysis of OVA-specific spleen cell proliferation activity: The experimental method is the same as in Example 1, r 2. Analysis of spleen cell proliferation activity, and 5 于 was added during cell culture. The 〇VA solution (1 //mL) was co-cultured to analyze the proliferative activity of OVA-specific spleen cells. 2. The amount of IFn_y secreted by OVA-specific cells: The experimental method was the same as that described in "3. IFN-γ secretion" of Example 1, and co-cultured with 50 L of OVA solution (100 pg/mL) during cell culture. The amount of IFN-γ secreted by OVA-specific spleen cells was analyzed. 3 Determination of the amount of OVA-specific IgG secreted in serum: The experimental method was as described in "1. Determination of total IgG in serum" in the first example, and 50 μM OVA solution (50 pg/mL) was applied to 96 wells in advance. The ELISA floppy disk is available overnight. The experimental design of the gold needle powder was formulated into high dose (94.5 mg / mL) and low 201004635 dose (10 · 5 mg / mL) of the Golden Needle solution in PBS, and the commercial Ganoderma lucidum powder powder was formulated into 6.55 mg / mL The solution was a positive control group and the phosphate buffer pBs was used as a negative control group. The mice were fed with 2 times of Flammulina velutipes solution or positive and negative control groups by tube feeding and feeding method, and fed for 4 days of continuous sacrifice. The first day of the first day and the third week was intra-abdominal injection (intraperit). 〇neai, ) OVA immunization, supplemented with adjuvant (2〇% KA1(s〇4)2.12H2〇) with a concentration of 100 μg of OVA (50 fluoro) at a concentration of 500 pg/mL as a specific antigen, Subsequent tests were carried out. In addition, it was compared to mice fed phosphate buffer without OVA treatment (i.e., naive group). The mouse spleen cells were co-cultured with OVA for 72 hours in vitro. 'The spleen cell proliferation activity of the mouse was determined by the above method; on the other hand, the cell culture medium was collected, and ΙρΝ_γ and IL_2 and Α清中〇VA were analyzed by the aforementioned method by ELISA. Specific lgG secretion. result

The results showed that feeding. High-dose Flammulina velutipes solution (equivalent to 丨8.9 mg/mouse dose) could significantly increase the proliferation activity of 〇VA-specific spleen cells in mice compared with the negative control group (p < 0.05) 'relative to the negative control group The percentage increase of proliferative activity in BrdU T analysis was 17.9% (Fig. 7); the amount of ΙΡΝγ secretion in two OVA-specific spleen cells was significantly higher than that in the negative control group (p< 〇〇 5), eight relative to negative The percentage increase of IFN_Y* secretion in the control group was M2% (Fig.)', which significantly increased the amount of 〇vA-specific WG secretion in the clearing of the mice (p< 〇.〇5) (Ninth panel). Example 3: Composition Formulation Containing Flammulina Mushroom Powder 19 201004635 The gold needle powder can be used in various forms of food & a specific embodiment is as follows: - Formulation: Made by the aforementioned method Flammulina powder; and natural glucose, sucrose, powder, vegetable oil and a small amount of emulsifier seasoning. This formula is (4) into a natural diet camp with a regulated immune response σσ

In summary, the present invention demonstrates the efficacy of Flammulina velutipes preparations in modulating the immune response in mammals, and the present invention demonstrates that each mouse (body weight of about 2 gram to 25 grams) is dosed at 2 2 〇 mg per ounce, or equivalent The dosage of 5G-5G0 g of fresh golden needles in the human body and the administration of the Flammulina velutipes powder of the present invention in a relative dose according to the present invention can effectively regulate the non-specific immune response and the specific immune response. The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, and any person having ordinary skill in the art can use the present invention without departing from the technical features of the present invention. Equivalent embodiments of the present invention have been modified or modified, and the technical features of the present invention are still within the scope of the technical features of the present invention. [Simplified description of the drawings] The first figure shows the museum Analysis of metabolic activity of spleen cells of mice infected with Flammulina velutipes. The second panel shows the spleen cell proliferation activity of mice infected with Flammulina velutipes 20 201004635 The results of the analysis. The third panel shows the effect of feeding Flammulina velutipes on the killing activity of natural killer cells in mouse spleen cells. The fourth panel shows the effect of feeding Flammulina velutipes on the IFN-γ secretion of mouse spleen cells. Figure 5 shows the effect of feeding Flammulina velutipes on the amount of IL-2 secreted by mouse spleen cells. Figure 6 shows the effect of feeding Flammulina velutipes on total IgG secretion in the serum of mice. Figure 7 shows the results of OVA-specific spleen cell metabolic activity in mice fed the Flammulina velutipes solution. Fig. 8 shows the results of analysis of the proliferation activity of OVA-specific spleen cells of mice fed with Flammulina velutipes solution. • Figure 9 shows the feeding of Flammulina velutipes for OVA specificity in mouse serum

The effect of IgG secretion. [Main component symbol description] 21

Claims (1)

201004635 X. Patent application scope · 1' Kind of food composition for regulating immune response, which contains golden mushroom powder (F/a coffee V coffee). 2. The food composition according to claim 1 of the patent scope, which is obtained by the following steps: providing a fresh mushroom body; and homogenizing the mushroom body into a liquid of Flammulina velutipes; drying the liquid of the mushroom to form a mushroom powder And the Flammulina velutipes powder is used as a food composition for regulating an immune response. 3. The food composition of claim 1, wherein the food composition is obtained by: providing a mushroom body; drying the mushroom body; and grinding the dried needle and the fruit body Obtaining Flammulina powder; The Flammulina velutipes powder is used as a food composition. The food composition according to the invention of the invention, wherein the mist is dried or dried by hot air at 50-95 ° C. 4. The dry step of the application is as follows: drying; 5. If the drying step of the patent application range is to dry by cold or 6. The food composition as described in claim 3, wherein the hot air drying is carried out at 50-95 °C. As described in any one of items 1 to 5, the food composition of π 7 is 22 201004635, which is taken in an amount of 1000 mg to 3 〇〇 () mg of enoki mushroom powder per kilogram of body weight per kilogram. 7. The food composition according to claim 6, wherein the food composition is administered in an amount of 500 mg to 2000 mg of enoki mushroom powder per kg of body weight per day. 8_ The food composition according to item 7 of the patent application, which is taken in an amount of 1 〇〇 mg to 1 〇〇〇 mg of enoki mushroom powder per kilogram of body weight per day. ❺ 9. A feed composition for modulating an immune response, comprising a mushroom powder. 10. The feed composition according to claim 9 of the patent application, which is obtained by the following steps: providing fresh Flammulina velutipes fruit body; homogenizing the Flammulina velutipes fruit body into a Flammulina velutipes liquid; drying the Jinzheng Yi liquid to form a Jinzhengyi..Powder.Wei and Lu will make the Flammulina velutipes powder into a feed composition for feeding animals and regulating their immune response. 11. The feed composition of claim 9, wherein the feed composition is obtained by the following steps: providing a mushroom body; drying the golden needle garlic; fruiting body; grinding the dried mushroom body to obtain Gold needle powder; and, the mushroom powder is made into a feed composition for use as a breeding animal and 23 201004635 to regulate its immune response. 12. The feed composition of claim 1, wherein the drying step is carried out by cold drying, spray drying or 5 〇 9 rc hot air drying. 13. The feed composition of claim 5, wherein the drying step is carried out by cold drying or 5 〇 9 rc hot air drying. The feed composition according to any one of the items 9 to 13 of the present invention, which is administered at a dose of 1000 mg to 3000 mg of the golden mushroom powder per kg of body weight per day. 15. The feed composition according to item 14 of the scope of the patent application is fed at a dose of 5 〇〇 mg to 2 〇〇〇 吕 。 。 。 。 。. 16. The feed composition of claim 15, wherein the feed composition is fed at a dose of from 10 mg per kg of body weight per day to a mg mg of the gold needle powder. ❷ I7· A pharmaceutical composition for modulating an immune response comprising a gold needle powder and a pharmaceutically acceptable carrier or excipient. The medicinal composition according to claim 17, wherein the enoki mushroom powder is obtained by the following steps: providing a fresh enoki mushroom fruit body; homogenizing the golden needle genus into a gold needle liquid; and drying the enoki mushroom The liquid forms a powder of Flammulina velutipes. 19. The pharmaceutical composition according to claim 17, wherein the enoki mushroom powder is obtained by the following steps: 24 201004635 providing a golden needle body; drying the enoki mushroom fruit body; and grinding the dried enoki mushroom Fruiting body to obtain Flammulina powder. 20. The pharmaceutical composition of claim 18, wherein the drying step is freeze drying, spray drying or 5 〇 95. Dry with hot air. 21. The pharmaceutical composition according to claim 19, wherein the drying step is carried out by freeze drying or hot air drying at 50_95 〇c. 22. The pharmaceutical composition according to any one of claims 17 to 21, which is administered in a single dose per dose or multiple doses per dose. 23. The pharmaceutical composition according to any one of claims 17 to 21, which is administered at a dose of 1 〇 mg to 3000 mg of acupuncture powder per kilogram of body weight per day. 24. The pharmaceutical composition according to claim 23, which is administered in a dose of 500 mg to 2000 mg of Flammulina velutipes powder per kg body weight per day. 25. The pharmaceutical composition according to claim 24, which is administered in an amount of from 1 mg to 1000 mg of enoki mushroom powder per kg of body weight per day. 25